TPST: Tempest Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 85.44
Enterprise Value ($M) 56.76
Book Value ($M) 26.77
Book Value / Share 1.21
Price / Book 3.19
NCAV ($M) 15.53
NCAV / Share 0.70
Price / NCAV 5.50

Profitability (mra)
Return on Invested Capital (ROIC) -0.62
Return on Assets (ROA) -0.79
Return on Equity (ROE) -2.69

Liquidity (mrq)
Quick Ratio 4.29
Current Ratio 4.29

Balance Sheet (mrq) ($M)
Current Assets 40.36
Assets 51.60
Liabilities 24.84
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -29.16
Net Income -29.49
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -27.36
Cash from Investing -0.17
Cash from Financing 35.60

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-14 13G/A Rock Springs Capital Management LP 0.00 -100.00
02-14 13G/A EcoR1 Capital, LLC 0.00 -100.00
02-09 13G/A Fmr Llc 2.24 -33.33
02-08 13D/A Versant Venture Capital VI, L.P. 11.00 0.00

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-19 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K
2023-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-08-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-12 146,819 51,272 286.35
2024-04-11 127,553 53,961 236.38
2024-04-10 137,801 92,752 148.57
2024-04-09 146,856 148,623 98.81
2024-04-08 270,180 93,796 288.05

(click for more detail)

Similar Companies
TIL – Instil Bio, Inc. TLSA – Tiziana Life Sciences Ltd
TNXP – Tonix Pharmaceuticals Holding Corp. TRAW – Traws Pharma, Inc.
TRVN – Trevena, Inc.


Financial data and stock pages provided by
Fintel.io